Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 1
2002 1
2010 1
2011 2
2012 2
2015 1
2016 3
2017 1
2018 5
2019 7
2020 7
2021 10
2022 11
2023 13
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.
Li Y, Lih TM, Dhanasekaran SM, Mannan R, Chen L, Cieslik M, Wu Y, Lu RJ, Clark DJ, Kołodziejczak I, Hong R, Chen S, Zhao Y, Chugh S, Caravan W, Naser Al Deen N, Hosseini N, Newton CJ, Krug K, Xu Y, Cho KC, Hu Y, Zhang Y, Kumar-Sinha C, Ma W, Calinawan A, Wyczalkowski MA, Wendl MC, Wang Y, Guo S, Zhang C, Le A, Dagar A, Hopkins A, Cho H, Leprevost FDV, Jing X, Teo GC, Liu W, Reimers MA, Pachynski R, Lazar AJ, Chinnaiyan AM, Van Tine BA, Zhang B, Rodland KD, Getz G, Mani DR, Wang P, Chen F, Hostetter G, Thiagarajan M, Linehan WM, Fenyö D, Jewell SD, Omenn GS, Mehra R, Wiznerowicz M, Robles AI, Mesri M, Hiltke T, An E, Rodriguez H, Chan DW, Ricketts CJ, Nesvizhskii AI, Zhang H, Ding L; Clinical Proteomic Tumor Analysis Consortium. Li Y, et al. Among authors: pachynski r. Cancer Cell. 2023 Jan 9;41(1):139-163.e17. doi: 10.1016/j.ccell.2022.12.001. Epub 2022 Dec 22. Cancer Cell. 2023. PMID: 36563681 Free PMC article.
Epigenetic regulation during cancer transitions across 11 tumour types.
Terekhanova NV, Karpova A, Liang WW, Strzalkowski A, Chen S, Li Y, Southard-Smith AN, Iglesia MD, Wendl MC, Jayasinghe RG, Liu J, Song Y, Cao S, Houston A, Liu X, Wyczalkowski MA, Lu RJ, Caravan W, Shinkle A, Naser Al Deen N, Herndon JM, Mudd J, Ma C, Sarkar H, Sato K, Ibrahim OM, Mo CK, Chasnoff SE, Porta-Pardo E, Held JM, Pachynski R, Schwarz JK, Gillanders WE, Kim AH, Vij R, DiPersio JF, Puram SV, Chheda MG, Fuh KC, DeNardo DG, Fields RC, Chen F, Raphael BJ, Ding L. Terekhanova NV, et al. Among authors: pachynski r. Nature. 2023 Nov;623(7986):432-441. doi: 10.1038/s41586-023-06682-5. Epub 2023 Nov 1. Nature. 2023. PMID: 37914932 Free PMC article.
Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.
Wu Y, Terekhanova NV, Caravan W, Naser Al Deen N, Lal P, Chen S, Mo CK, Cao S, Li Y, Karpova A, Liu R, Zhao Y, Shinkle A, Strunilin I, Weimholt C, Sato K, Yao L, Serasanambati M, Yang X, Wyczalkowski M, Zhu H, Zhou DC, Jayasinghe RG, Mendez D, Wendl MC, Clark D, Newton C, Ruan Y, Reimers MA, Pachynski RK, Kinsinger C, Jewell S, Chan DW, Zhang H, Chaudhuri AA, Chheda MG, Humphreys BD, Mesri M, Rodriguez H, Hsieh JJ, Ding L, Chen F. Wu Y, et al. Among authors: pachynski rk. Nat Commun. 2023 Mar 27;14(1):1681. doi: 10.1038/s41467-023-37211-7. Nat Commun. 2023. PMID: 36973268 Free PMC article.
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Sharma P, et al. Among authors: pachynski rk. Cancer Cell. 2020 Oct 12;38(4):489-499.e3. doi: 10.1016/j.ccell.2020.08.007. Epub 2020 Sep 10. Cancer Cell. 2020. PMID: 32916128 Free article. Clinical Trial.
Reply by Authors.
Crawford ED, Garnick MB, Eckel RH, Miner MM, Freedland SJ, Pachynski RK, Wassersug RJ, Rosenberg MT, Walker LM, Fairman C, Curley T, Crosby M, Lin PH, Hafron JM. Crawford ED, et al. Among authors: pachynski rk. Urol Pract. 2024 Jan;11(1):30-31. doi: 10.1097/UPJ.0000000000000473.02. Epub 2023 Nov 6. Urol Pract. 2024. PMID: 38051218 No abstract available.
How else can we approach prostate cancer biomarker discovery?
Drake RR, Angel PM, Wu J, Pachynski RK, Ippolito JE. Drake RR, et al. Among authors: pachynski rk. Expert Rev Mol Diagn. 2020 Feb;20(2):123-125. doi: 10.1080/14737159.2019.1665507. Epub 2019 Sep 10. Expert Rev Mol Diagn. 2020. PMID: 31498690 Free PMC article. No abstract available.
Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance.
Sridaran D, Chouhan S, Mahajan K, Renganathan A, Weimholt C, Bhagwat S, Reimers M, Kim EH, Thakur MK, Saeed MA, Pachynski RK, Seeliger MA, Miller WT, Feng FY, Mahajan NP. Sridaran D, et al. Among authors: pachynski rk. Nat Commun. 2022 Nov 14;13(1):6929. doi: 10.1038/s41467-022-34724-5. Nat Commun. 2022. PMID: 36376335 Free PMC article.
Treatment of Advanced Prostate Cancer.
Thomas TS, Pachynski RK. Thomas TS, et al. Among authors: pachynski rk. Mo Med. 2018 Mar-Apr;115(2):156-161. Mo Med. 2018. PMID: 30228709 Free PMC article. Review.
63 results